There is disclosed a process for preparing 1,5-benzothiazepine derivatives of the formula: ##STR1## wherein r1 is a lower alkyl group, or a salt thereof which comprises subjecting a propionate derivatives of the formula: ##STR2## wherein r2 is an ester residue and r1 is the same as defined above, to intramolecular cyclization in the presence of a sulfonic acid compound of the formula:
r3 SO3 H (III)
wherein r3 is a lower alkyl group or a substituted or unsubstituted phenyl group, in a non-halogenated organic solvent and, if desired, converting the product to a salt thereof.
|
1. A process for preparing 1,5-benzothiazepine derivatives of the formula: ##STR6## wherein r1 is a lower alkyl group, or a salt thereof which comprises subjecting a propionate derivative of the formula: ##STR7## wherein r2 is a lower alkyl group and r1 is the same as defined above, to intramolecular cyclization in the presence of a sulfonic acid compound of the formula:
r3 SO3 H (III) wherein r3 is a lower alkyl group or a substituted or unsubstituted phenyl group, in a non-halogenated aromatic solvent and, optionally converting the product to a salt thereof. 8. A process for preparing 3-acetoxy-5-(β-dimethylaminoethyl)-2,3-dihydro-1,5-benzothiazepine derivatives of the formula: ##STR8## wherein r1 is a lower alkyl group, or a pharmaceutically acceptable salt thereof, which comprises the steps of:
a) subjecting a propionate derivative of the formula: ##STR9## wherein r2 is a lower alkyl group and r1 is the same as defined above, to intramolecular cyclization in the presence of a sulfonic acid compound of the formula:
r3 SO3 H (III) wherein r3 is a lower alkyl group or a substituted or unsubstituted phenyl group, in a non-halogenated aromatic solvent to give a 1,5-benzothiazepine derivative of the formula: ##STR10## wherein r1 is the same as defined above, and b) converting the compound (I) to the corresponding 3-acetoxy-5-(β-dimethylaminoethyl)-1,5-benzothiazepine derivative or a pharmaceutically acceptable salt thereof. 2. A process according to
3. A process according to
4. A process according to
5. A process according to
6. A process according to
7. A process according to
|
This application is a continuation of application Ser. No. 07/659,663, filed Feb. 25, 1991, the contents of which are hereby incorporated herein by reference now abandoned.
This invention relates to a novel process for preparing 1,5-benzothiazepine derivatives of the formula: ##STR3## wherein R1 is a lower alkyl group, or a salt thereof.
The above 2-(4-lower alkoxyphenyl)-3-hydroxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is useful as an intermediate for the synthesis of medical compounds, for the example, (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-(β-dimethylaminoethy l)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (generic name: Diltiazem) which is excellent coronary vasodilator.
Heretofore, there have been known that said intermediate can be prepared by the two steps of, for example, hydrolyzing ethyl 2-hydroxy-3-(2-aminophenylthio)-3-(4-methoxyphenyl)propionate with alkali to give corresponding free acid and then subjecting it to intramolecular cyclization under heating (Japanese Patent Publication (examined) No. 8982/1971).
It is an object of the present invention to provide a novel process for preparing said intermediates from 2-hydroxy-3-(2-aminophenylthio)-3-(4-lower alkoxyphenyl)propionate in a high yield by one step.
According to the present invention, 1,5-benzothiazepine derivatives of the formula (I) can be prepared by subjecting a propionate derivative of the formula: ##STR4## wherein R2 is an ester residue and R1 is the same as defined above, to intramolecular cyclization in the presence of a sulfonic acid compound of the formula:
R3 SO3 H (III)
wherein R3 is a lower alkyl group or a substituted or unsubstituted phenyl group, in a non-halogenated organic solvent.
The ester residue represented by R2 of the starting compound (II) may be any groups which are not concerned with the reaction, for example, a lower alkyl group.
Examples of the sulfonic acid compound (III) to be used in the intramolecular cyclization include, for example, the compound wherein R3 of the formula (III) is an alkyl group having 1 to 4 carbon atoms such as methyl group, ethyl group, propyl group or butyl group or phenyl group which may be substituted by at least one of these alkyl groups. Among them, more preferred are methanesulfonic acid and p-toluenesulfonic acid. An amount of the sulfonic acid compound is not particularly limited but generally, it is preferably used at an amount of about 0.1 to 10 w/w %, more preferably about 0.5 to 6 w/w %, based on the compound (II).
The solvents used in the invention are not particularly limited and any of a non-halogenated organic solvent which will not hinder the reaction can be used. Examples of such solvents include a high boiling point solvent, for example, ethers such as n-propyl ether, n-butyl ether, isobutyl ether, n-pentyl ether or dioxane; non-halogenated aromatic solvents such as xylene, toluene, ethylbenzene, isobutylbenzene, isopropylbenzene, n-propylbenzene or anisole; aliphatic hydrocarbons such as n-pentan, n-ocotane or n-nonane.
It is especially preferred to use toluene, ethylbenzene or xylene. It is preferable to carry out intramolecular cyclization at 90° to 160°C in the above mentioned solvent, especially 110° to 145°C Since the above-mentioned reaction is carried out without racemization, the desired compound (I) in the optically active form can be obtained by using the optically active compound (II) as the starting material.
The desired compound (I) thus obtained can be converted to the corresponding 3-acetoxy-5-(β-dimethylaminoethyl)-2,3-dihydro-1,5-benz othiazepine derivatives of the formula: ##STR5## wherein R1 is the same as defined above, or a pharmaceutically acceptable salt thereof in a known method, for example, in a method described in Japanese Patent Publication (examined) Nos. 18038/1978 and 43785/1971 and U.S. Pat. Nos. 3,562,257 and 4,438,035, the contents of which are hereby incorporated herein by reference.
According to the process of the present invention, 1,5-benzothiazepine derivatives (I) can be obtained in a high yield of more than 85% by one step. Therefor, as compared with the known methods, the process of the invention is extremely excellent for the industrial process.
Further, when the starting compound (II) is prepared by reacting 2-aminothiophenol with 2,3-epoxy-3-(4-lower alkoxyphenyl) propionate in a non-halogenated organic solvent used in the invention, the reaction mixture can be subjected to the intramolecular cyclization without isolating said starting compound (II) from the mixture. In this case, the process of the present invention is advantageous for the industrial scale in that the desired compound (I) can be obtained from epoxy compounds by a substantially single reaction operation in a short time and a high yield.
When the intramolecular cyclization is carried out in the absence of the sulfonic acid compound (III) of the invention, a long time and a high temperature of 160° to 180°C is required for the reaction and the yield of the desired compound is insufficient.
However, according to the process of the present invention, the reaction can be completed in a shorter time at a lower temperature as compared with the above case and the yield of the desired compound (I) is high.
Throughout the specification and Claims, the term "lower alkyl" and "lower alkoxy" are interpreted as the alkyl of 1 to 4 carbon atoms and alkoxy of 1 to 4 carbon atoms, respectively.
A mixture of 40 g of methyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, 26.5 g of 2-aminothiophenol and 300 ml of xylene is heated at 110° to 120°C for 1 hour, whereby the reaction mixture containing methyl (2S,3S)-3-[(2-aminophenyl)thiol]-2-hydroxy-3-(4-methoxylphenyl)propionate is obtained. 380 mg of methanesulfonic acid are added to the mixture and the mixture is refluxed for 7 hours. During the reaction, methanol formed is removed by the azeotropic distillation with xylene. The mixture is cooled to under 10°C and then stirred for 1 hour. Precipitated crystals are collected by filtration, washed with cooled methanol and then dried, whereby 49.1 g of (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H) -one are obtained. Yield: 84.8% m.p.: 204°-205°C [α]D20 +115° (c=0.5, dimethylformamide)
A mixture of 40 g of methyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, 26.5 g of 2-aminothiophenol and 300 ml of toluene is heated at 110° to 115°C for 1 hour, whereby the reaction mixture containing methyl (2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxylphenyl)propionate is obtained. After cooled to 80° to 90°C, 1.5 g of methanesulfonic acid are added to the mixture and the mixture is refluxed for 18 hours. During the reaction, methanol formed is removed by the azeotropic distillation with toluene. Then the mixture is treated in the same manner as described in Example 1, whereby 46.9 g of (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzeothiazepine-4(5 H)-one are obtained. Yield: 81.0% m.p.: 203°-204°C [α]D20 +115° (c=0.5, dimethylformamide)
A mixture of 40 g of methyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, 26.5 g of 2-aminothiophenol and 250 ml of xylene is heated at 110° to 120°C for 1 hour, whereby the reaction mixture containing methyl (2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxylphenyl)propionate is obtained. 600 mg of p-toluenesulfonic acid hydrate are added to the mixture and the mixture is refluxed for 8 hours. During the reaction, methanol formed is removed by the azeotropic distillation with xylene. Then the mixture is treated in the same manner as described in Example 1, whereby 47.5 g of (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H) -one are obtained. Yield: 82.1% m.p.: 203°-204°C [α]D20 +115° (c=0.5, dimethylformamide)
Oine, Toyonari, Seto, Masahiko, Hayashi, Hironori, Koumoto, Tadayuki, Kadowaki, Toshiya
Patent | Priority | Assignee | Title |
5847122, | Feb 23 1996 | Tanabe Seiyaku Co., Ltd. | Process for preparing 1,5-benzothiazepine derivative |
5859241, | Mar 22 1996 | DSM N V | Process for the preparation of a benzothiazepine |
Patent | Priority | Assignee | Title |
3562257, | |||
4438035, | Dec 07 1981 | Tanabe Seiyaku Co., Ltd. | Method of preparing benzothiazepine derivatives |
4474956, | Jul 07 1982 | Siegfried Aktiengesellschaft | Process for the preparation of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide |
5008411, | May 24 1988 | Hoffmann-La Roche Inc.; Hoffmann-La Roche Inc | Glycidic acid ester and process of preparation |
5013835, | Sep 14 1989 | sanofi-aventis | Method of preparing (+)-(2S,3S)-3-hydroxy-2-(4-methoxyphenyl)2,3-dihydro-5H-1,5-benzothiazep ine-4-one |
5055575, | Apr 12 1990 | Tanabe Seiyaku Co., Ltd. | Process for preparing 1,5-benzothiazepine derivatives |
5102998, | Jan 11 1989 | Synthelabo | Method for preparing (+)-(2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-5H-1,5-benzothiaze pine-4-one and chlorinated derivatives thereof |
5144025, | Apr 02 1990 | Zambon Group S.p.A. | Process for the resolution of intermediates useful in the preparation of 1,5-benzothiazepines |
EP98422, | |||
EP343474, | |||
EP378455, | |||
EP392543, | |||
EP395302, | |||
EP395323, | |||
JP4643785, | |||
JP468982, | |||
JP5318038, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Nov 19 1992 | Tanabe Seiyaku Co., Ltd. | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Aug 22 1997 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
May 28 1999 | ASPN: Payor Number Assigned. |
Oct 09 2001 | REM: Maintenance Fee Reminder Mailed. |
Mar 15 2002 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Mar 15 1997 | 4 years fee payment window open |
Sep 15 1997 | 6 months grace period start (w surcharge) |
Mar 15 1998 | patent expiry (for year 4) |
Mar 15 2000 | 2 years to revive unintentionally abandoned end. (for year 4) |
Mar 15 2001 | 8 years fee payment window open |
Sep 15 2001 | 6 months grace period start (w surcharge) |
Mar 15 2002 | patent expiry (for year 8) |
Mar 15 2004 | 2 years to revive unintentionally abandoned end. (for year 8) |
Mar 15 2005 | 12 years fee payment window open |
Sep 15 2005 | 6 months grace period start (w surcharge) |
Mar 15 2006 | patent expiry (for year 12) |
Mar 15 2008 | 2 years to revive unintentionally abandoned end. (for year 12) |